Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 36 Leukemia 26 Precursor Cell Lymphoblastic Leukemia-Lymphoma 15 Gastrointestinal Stromal Tumors 13 Leukemia, Myeloid, Chronic-Phase 12 Leukemia, Myeloid 6 Brain Neoplasms 6 Prostatic Neoplasms 5 Philadelphia Chromosome 5 Blast Crisis 5 Sarcoma 4 Recurrence 4 Glioblastoma 4 Carcinoma, Non-Small-Cell Lung 4 Bone Marrow Diseases 4 Ovarian Neoplasms 3 Melanoma 3 Lung Neoplasms 3 Leukemia, Myeloid, Acute 3 Hematologic Diseases 3 Bronchiolitis Obliterans Syndrome 3 Breast Neoplasms 3 Stomach Neoplasms 2 Polycythemia Vera 2 Neurofibromatoses 2 Neoplasms by Histologic Type 2 Neoplasms 2 Neoplasm Metastasis 2 Myeloproliferative Disorders 2 Meningioma 2

Interventions

Sirolimus 5 Everolimus 4 carbon-11 acetate 1 Sugars 1 Simvastatin 1 Resveratrol 1 Octreotide 1 Letrozole 1 Imatinib Mesylate 1 Hydroxychloroquine 1 Celecoxib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Lymphangioleiomyomatosis × Imatinib Mesylate × Clear all

NCT03131999 2020-06-16

LAMP-1

Medical University of South Carolina

Phase 1/2 Completed

18 enrolled 7 charts

Lymphangioleiomyomatosis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡